VEGFR-2 (a.a.1304-1317) Blocking Peptide
€155.00
In stock
SKU
ECM-VX2875
Background:
Vascular endothelial growth factor receptor-2 (VEGFR-2/Flk-1/KDR) is the primary receptor for VEGF in endothelial cells. Other VEGFR family members, VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4), can also transduce the intracellular signals of VEGF. However, the role of VEGFR-1 is observed mainly during embryonic angiogenesis and VEGFR-3 signaling may be restricted to specific types of endothelial cells. Major autophosphorylation sites of VEGFR-2 are located in the kinase insert domain (Tyr-951/996) and in the tyrosine kinase catalytic domain (Tyr-1054/1059). Other sites, Tyr-1175 and Tyr-1212 provide docking sites for downstream signaling molecules. Activation of VEGFR-2 also phosphorylates Tyr-801, leading to PI3-kinase-Akt activation and increases in endothelial nitric oxide synthase activity. Phosphorylation of mutliple sites in VEGFR-2 is required for downstream activation of several signaling pathways that control proliferation, chemotaxis, and sprouting during angiogenesis.
Sequence: A synthetic peptide corresponding to amino acids 1304 to 1317 in human VEGFR-2. This sequence has high homology to rat and mouse VEGFR-2, and no significant homology to other VEGFR family members.
Specificity: The peptide is specifically recognized by anti-VEGFR-2 (a.a. 1304-1317) antibody (VP2871) in ELISA, and has been shown to block the reactivity of VP2871 during Western blot. In addition, the peptide is recommended for use in blocking VP2871 reactivity in immunocytochemistry.
Application dilution:
Blocking: 1:1000
ELISA: 50 ng/well
End user should determine optimal dilution for their particular applications and experiments.Western blot membranes were incubated with diluted antibody in 5% non-fat milk, PBS, 0.04% Tween20 for 1 hour at room temperature.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
Vascular endothelial growth factor receptor-2 (VEGFR-2/Flk-1/KDR) is the primary receptor for VEGF in endothelial cells. Other VEGFR family members, VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4), can also transduce the intracellular signals of VEGF. However, the role of VEGFR-1 is observed mainly during embryonic angiogenesis and VEGFR-3 signaling may be restricted to specific types of endothelial cells. Major autophosphorylation sites of VEGFR-2 are located in the kinase insert domain (Tyr-951/996) and in the tyrosine kinase catalytic domain (Tyr-1054/1059). Other sites, Tyr-1175 and Tyr-1212 provide docking sites for downstream signaling molecules. Activation of VEGFR-2 also phosphorylates Tyr-801, leading to PI3-kinase-Akt activation and increases in endothelial nitric oxide synthase activity. Phosphorylation of mutliple sites in VEGFR-2 is required for downstream activation of several signaling pathways that control proliferation, chemotaxis, and sprouting during angiogenesis.
Sequence: A synthetic peptide corresponding to amino acids 1304 to 1317 in human VEGFR-2. This sequence has high homology to rat and mouse VEGFR-2, and no significant homology to other VEGFR family members.
Specificity: The peptide is specifically recognized by anti-VEGFR-2 (a.a. 1304-1317) antibody (VP2871) in ELISA, and has been shown to block the reactivity of VP2871 during Western blot. In addition, the peptide is recommended for use in blocking VP2871 reactivity in immunocytochemistry.
Application dilution:
Blocking: 1:1000
ELISA: 50 ng/well
End user should determine optimal dilution for their particular applications and experiments.Western blot membranes were incubated with diluted antibody in 5% non-fat milk, PBS, 0.04% Tween20 for 1 hour at room temperature.
Buffer/Storage:
Blocking Peptide is supplied in 50µl phosphate-buffered saline and 0.05% sodium azide. Store at –20°C. Stable for 1 year.
| Is Featured? | No |
|---|
Write Your Own Review